Indication

nivolumab with ipilimumab (NIVO+IPI) is indicated for the treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-based combination chemotherapy.

Medicine details

Medicine name:
nivolumab (Opdivo)
SMC ID:
SMC2394
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
13 December 2021
SMC meeting date:
TBC
Patient group submission deadline:
04 October 2021